Ironwood Pharmaceuticals, Inc.
IRWD
$0.8396
$0.0354.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 317.68M | 351.41M | 378.42M | 400.57M | 413.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 317.68M | 351.41M | 378.42M | 400.57M | 413.55M |
| Cost of Revenue | 9.17M | 7.55M | 26.77M | 29.73M | 19.12M |
| Gross Profit | 308.51M | 343.86M | 351.65M | 370.84M | 394.44M |
| SG&A Expenses | 130.53M | 143.87M | 157.25M | 153.48M | 148.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 243.57M | 255.29M | 282.66M | 281.85M | 266.26M |
| Operating Income | 74.11M | 96.12M | 95.76M | 118.72M | 147.30M |
| Income Before Tax | 23.97M | 65.20M | 71.56M | 86.13M | -1.01B |
| Income Tax Expenses | 56.31M | 64.32M | 74.68M | 78.94M | 72.46M |
| Earnings from Continuing Operations | -32.34 | 0.88 | -3.12 | 7.18 | -1.08K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 658.00K | 2.03M | 29.32M |
| Net Income | -32.34M | 880.00K | -2.46M | 9.21M | -1.05B |
| EBIT | 74.11M | 96.12M | 95.76M | 118.72M | 147.30M |
| EBITDA | 76.09M | 98.13M | 97.80M | 120.36M | 149.10M |
| EPS Basic | -0.20 | 0.01 | -0.02 | 0.06 | -6.77 |
| Normalized Basic EPS | 0.18 | 0.27 | 0.27 | 0.38 | 0.72 |
| EPS Diluted | -0.20 | 0.00 | -0.02 | 0.04 | -6.79 |
| Normalized Diluted EPS | 0.18 | 0.27 | 0.27 | 0.35 | 0.69 |
| Average Basic Shares Outstanding | 639.14M | 635.87M | 632.43M | 628.61M | 624.97M |
| Average Diluted Shares Outstanding | 639.67M | 636.40M | 632.96M | 659.62M | 655.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |